ABOS - Acumen Pharmaceuticals Inc
IEX Last Trade
2.73
-0.080 -2.930%
Share volume: 232,256
Last Updated: Fri 30 Aug 2024 09:59:57 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$2.81
-0.08
-2.85%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
-5.84%
1 Month
-19.88%
3 Months
-8.05%
6 Months
-34.29%
1 Year
-56.92%
2 Year
-47.81%
Key data
Stock price
$2.73
DAY RANGE
N/A - N/A
52 WEEK RANGE
$1.81 - $6.30
52 WEEK CHANGE
-$0.55
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/14/2024
Company detail
CEO:
Region: US
Website: acumenpharm.com
Employees: 1
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: acumenpharm.com
Employees: 1
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
acumen is forging a new path towards safe and effective treatments for alzheimer’s disease and other neurodegenerative diseases through our focus on the biology of toxic amyloid-beta oligomers. our founders pioneered seminal discoveries and methods to understand the role of toxic amyloid-beta oligomers (aβo) in synaptic dysfunction and neurodegeneration. these early insights have fostered decades of research on the biology of aβo at acumen and throughout the field. we are now on the on cusp of realizing the therapeutic potential of aβo targeted drugs.
Recent news